TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Results of Operations and Financial Condition
Item 2.02
On March 18, 2019, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2018. A copy of the press release that discusses this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report.
|
Item 7.01 |
Regulation FD Disclosure |
The Company updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibit 99.02, 99.03 and 99.04 hereto and incorporated herein by reference
| Item 9.01 | Financial Statements and Exhibits. |
| (d) |
Exhibit No. |
Description. |
| 99.01 | Press Release dated March 18, 2019, issued by the Company | |
| 99.02 | Corporate Presentation by the Company for March 2019 (Long Form) | |
| 99.03 | Corporate Presentation by the Company for March 2019 (Short Form) | |
| 99.04 | Corporate Presentation by the Company for March 2019 (Abbreviated Form) |
Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm PRESS RELEASE Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.01 Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Initiated and Enrolling Topline Data Expected First Half 2020 NEW YORK,…
To view the full exhibit click here
